David Onions, Ph.D., appointed Chief Scientific Officer of BioReliance Corporation
PRNEWSWIRE
ROCKVILLE, Md., April 30 /PRNewswire/ -- BioReliance Corporation announced
today that David Onions, Ph.D., has been appointed Chief Scientific Officer,
effective June 18, 2007. Dr. Onions will be responsible for leading
BioReliance's global scientific efforts across preclinical and clinical
activities, including the development of enhanced assay systems, consulting
with key customers and partnering with regulatory agencies. Dr. Onions will
be joining BioReliance from Invitrogen Corporation where he has held the role
of Chief Medical Officer since 2005.
Previously, Dr. Onions was a founder and director of Q-One Biotech
Limited, a company well-known for its innovative biosafety testing and cGMP
manufacturing services, headquartered in Glasgow, Scotland. Q-One Biotech was
acquired by BioReliance in 2003, at which time Dr. Onions joined BioReliance
as the company's Chief Scientific Officer prior to accepting his most recent
role with Invitrogen.
"We are delighted to have David returning to a scientific leadership role
with BioReliance," stated Tim Derrington, President and CEO of BioReliance
Corporation. "As a founder of Q-One Biotech and a pioneer of biologics safety
testing, Dr. Onions' vision and enthusiasm for preclinical and clinical
services, combined with his technical expertise in areas of virology,
vaccines, and gene therapies, will ensure BioReliance pursues and delivers
leading-edge science as part of our contract bioservices offering. Scientific
excellence has been a hallmark of BioReliance for the past 60 years and we
look forward to working with David and expanding a world-class scientific team
under his leadership."
Dr. Onions' commented, "I am delighted to be returning to a business area
that's so close to my heart, and look forward to reaffirming BioReliance's
pre-eminence in both science and service. Now that monoclonal antibodies have
become mainstream medicines, our role in safe-guarding patients' well-being
has never been more critical. The development of new therapeutic modalities,
ranging from stem cells to RNAi treatments, will require us to respond with
equally innovative testing assays."
In addition to his Chief Scientific Officer role with BioReliance, Dr.
Onions will continue to serve on the boards of several international health
care organizations, including the World Health Organization's Expert Advisory
Panel on Biological Standardization and the UK Stem Cell Foundation Grants
Advisory Board. Previously, Dr. Onions served on the United States Food and
Drug Administration's Advisory Committee on Xenotransplantation.
Dr. Onions holds a Ph.D. from the University of Cambridge, is a fellow of
the Institute of Medical Sciences, a fellow of the Royal Society of Scotland,
and was formerly a professor of veterinary virology at the University of
Glasgow.
About BioReliance
BioReliance Corporation is a leading contract services organization,
offering more than 1,000 tests or services related to biologics safety
testing, in vitro and in vivo toxicology, viral manufacturing and lab animal
health diagnostics for the biopharmaceutical and pharmaceutical industries.
The company provides cost-effective services to over 600 clients annually,
including most of the largest pharmaceutical and biopharmaceutical companies
in the world. BioReliance has its primary facilities in Rockville, Maryland;
Glasgow, Scotland; and Stirling, Scotland. Headquartered in Rockville,
Maryland, BioReliance employs over 700 people globally. For more information,
visit http://www.bioreliance.com.
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
News
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All